Shane Ward
About Shane Ward
Shane Ward's Title: COO and CLO
Shane Ward holds dual roles as Chief Operating Officer and Chief Legal Officer. With these positions, he combines extensive operational and legal expertise to contribute to organizational leadership and strategic development. Ward's integration of these two critical areas supports effective decision-making and governance in the companies he serves, drawing from his robust background in both law and biopharmaceuticals.
Shane Ward's Education and Expertise
Shane Ward holds a Juris Doctor (J.D.) degree from the Georgetown University Law Center and a Bachelor of Arts (B.A.) degree from the University of Virginia. His legal education and training, complemented by over 25 years of experience, make him a highly skilled attorney and executive within the biopharmaceutical industry. These academic credentials have enabled Ward to lead with a nuanced understanding of both legal and business landscapes.
Shane Ward's Background in Biopharmaceuticals
Shane Ward has over 25 years of experience in the biopharmaceutical industry. Throughout his career, he has held significant legal and operational positions at notable companies such as Gilead Sciences, Human Genome Sciences, and Versartis. His expertise spans across legal practices and operational strategies, making him a valuable asset in the sector's diverse settings.
Shane Ward's Role at Bellicum Pharmaceuticals
Before his current roles, Shane Ward served as Chief Legal and Strategy Officer at Bellicum Pharmaceuticals, a clinical-stage cell therapy company. In this capacity, he provided leadership on legal matters and strategic initiatives, contributing to the company's development in the field of cell therapy. This role allowed Ward to leverage both his legal background and strategic thinking.
Shane Ward's Early Legal Career
Shane Ward began his legal career with Sidley Austin, an international law firm, where he was part of the FDA regulatory practice group. This role marked the start of his extensive career in legal and regulatory affairs within the healthcare sector. His early experience in FDA regulation has continued to inform his contributions to the biopharmaceutical industry.